FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D C	20540
wasnington,	D.C.	20049

STATEMENT	OF CHANGE	S IN BENEFICIAL	_ OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*  Fruchtman Steven M			2. Issuer Name <b>and</b> Ticker or Trading Symbol Onconova Therapeutics, Inc. [ ONTX ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)								
												X	Director Officer (	nive title		10% Ov Other (s	·		
(Last)	(Firs	st) (I	Middle)			3. Date of Earliest Transaction (Month/Day/Year)							X	below) "	-		below)	·	
375 PHEASANT RUN					02/17/2021									President, Chief Executive Off				f	
(Street) NEWTOW	VN PA	1	8940									5. Indi Line)					icable		
(City)	(Sta	te) (Z	Zip)											Form filed by More than One Reporting Person				ng	
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3)  2. Transa Date (Month/L				2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)  4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4)				and 5) Securities Beneficiall Owned Fol		Form y (D) or		Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership				
									Code	v	Amount	(A) or (D)	Pric	e	Reported Transactio (Instr. 3 an	on(s)			Instr. 4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
Derivative Conversion Date Execution I Security or Exercise (Month/Day/Year) if any		3A. Deemed Execution Dar if any (Month/Day/Yo	Code (Instr.					Expiration Date of Securit (Month/Day/Year) Underlyin		curities lying ative Security		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s	s silly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code	ode	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amou or Numb of Sha	er		(Instr. 4)			
Stock Appreciation Right	\$1.51	02/17/2021			A		706,000		(1)		02/17/2031	Common Stock <sup>(2)</sup>	706,0	000	\$0	706,00	00	D	

## **Explanation of Responses:**

- 1. These stock appreciation rights vest over three years, one-third on the first anniversary of the date of grant and thereafter in 24 equal monthly installments over the following two years.
- 2. These stock appreciation rights represent the right to receive a cash payment equal to the excess, if any, of (i) the fair market value of each underlying share of the Company's common stock, determined on the date of exercise minus (ii) the exercise price; provided, that in no event may the cash payment for each stock appreciation right exceed \$1.03, which is the maximum price per share of \$2.54, minus the base amount of \$1.51, subject to adjustment in accordance with the terms of the award agreement.

/s/ Mark Guerin as attorney-in-

\*\* Signature of Reporting Person

Date

02/19/2021

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.